神经营养性酪氨酸受体激酶抑制剂时代婴儿纤维肉瘤治疗的国际共识与争议
该国际共识基于欧洲172例婴儿纤维肉瘤患者的回顾性数据,分析了传统手术/化疗与TRK抑制剂的应用。传统保守策略对局部或广泛肿瘤有效但伴急慢性副作用;TRKI在多数患儿中起效迅速且急性毒性有限。共识建议局部病变可个体化选择传统化疗或TRKI,转移性疾病及传统化疗失败需截肢前应考虑TRKI。
要点
- 局部病变可个体化选择传统化疗或TRKI,需医患共同决策。
- 转移性疾病及传统化疗失败需截肢前应考虑TRKI。
- 传统保守策略有效但伴急慢性副作用,TRKI起效快且急性毒性有限。
核心结论
- 传统保守策略在TRK抑制剂时代前对婴儿纤维肉瘤有效但伴副作用;TRKI起效迅速且急性毒性有限。
- 局部病变可个体化选择传统化疗或TRKI;转移性疾病及传统化疗失败需截肢前应考虑TRKI。
研究设计与样本
- 国际共识:分析欧洲儿童软组织肉瘤研究组和CWS的172例婴儿纤维肉瘤回顾性数据,并与儿童肿瘤组制定共识策略。
主要发现
- 129例手术患者中118例(91%)行保守手术;9例死于疾病,1例死于毒性(6%),20例(12%)存活伴主要功能缺陷或行毁损手术。
关键数值与推荐
- TRKI在绝大多数婴儿纤维肉瘤患儿中显示非常快速的反应且急性毒性有限。
- 局部病变:传统化疗和TRKI均为选项,由医生和家长酌情决定。
- 转移性疾病及传统化疗失败需截肢前应考虑TRKI。
临床怎么用
- 局部病变可个体化选择传统化疗或TRKI,需医患共同决策。
- 转移性疾病及传统化疗失败需截肢前应考虑TRKI。
局限性
- 局部病变一线使用传统化疗还是TRKI缺乏共识,需额外数据。
- 临床试验外需更多数据解决一线选择争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted neurotrophic tropomyosin receptor kinase (TRK) inhibitors offer a highly specific therapeutic option for patients with infantile fibrosarcoma (IFS) carrying the NTRK gene translocation. International recommendations are needed to define the role of TRK inhibitors (TRKI) for infants with IFS. We analysed retrospective data for all published patients with IFS in the European Paediatric Soft tissue sarcoma Study Group and Cooperative Weichteilsarkomstudiengruppe (CWS) experience and developed a consensus strategy with the Children's Oncology Group. Therapies consisted of tumour resection and/or perioperative chemotherapy for extensive tumours. Among the 172 European patients treated, 162 were alive at the end of the follow-up. Sixty-five patients (40% of all survivors) were treated with surgery alone and 64 patients (39%) with surgery combined with chemotherapy. Radiotherapy was delivered to 3% of survivors (five patients). In addition, 28 survivors (17%) exclusively received chemotherapy. Among the 129 patients treated with surgery, 91% had conservative surgery (118 cases). Overall, nine patients died of disease, one from toxicity (6%) and 20 patients (12%) survived with major functional deficits or had mutilating surgery. Overall, conventional conservative strategies before the era of targeted therapy, even in the case of extensive tumours, demonstrate efficacy in IFS, but are associated with acute and some chronic side effects. TRKI have demonstrated very rapid responses in the vast majority of children with IFS with limited acute toxicity. With the current state of our knowledge, both conventional chemotherapy and TRKI should be regarded as options for patients with localised disease at the physician's and parent's discretion. TRKI should be considered in patients with metastatic disease, and before mutilating surgery when conventional chemotherapy fails. Outside a clinical trial, additional data are needed to resolve the lack of consensus about front-line use of conventional chemotherapy versus TRKI in patients with localised disease.
引用
- Orbach D, Sparber-Sauer M, Laetsch TW, et al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. Eur J Cancer. 2020. PMID: 32784118. doi:10.1016/j.ejca.2020.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。